REUTELINGSPERGER, CHRISTIAAN PETER MARIA,MOONEN, PETER JOZEF JACOBUS,VERMAIRE, ADRIAAN THOMAS
申请号：
CA2764029
公开号：
CA2764029C
申请日:
2010.06.03
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
An Annexin A5 variant, comprising one or more RGD (Arg-Gly-Asp) sequences, issuitable for use in the treatmentof a disease in mammals, including humans, wherein augmentation ofphagocytosis is a desired effect of treatment. TheAnnexin A5 variant can e.g. be used in the treatment of chronic inflammatorydiseases such as atherosclerotic plaque or in thetreatment of COPD. At least one RGD sequence may substitute sequences of threeamino acids within the range 1-19or other regionsof the amino acid sequences of Annexin A5； alternatively one or more RGDsequences may be part of an extension at the N-terminalside.
